CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (USD $)	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Total Comprehensive Income (Loss)	(Accumulated Deficit) Retained Earnings
Beginning Balance at Dec. 31, 2010	$ 246,008,876	$ 3,110	$ 243,004,522	$ (2,400,731)	$ 5,401,975
Beginning Balance (in shares) at Dec. 31, 2010		31,102,682
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Repurchase of stock for tax withholdings (in shares)		(31,263)
Repurchase of stock for tax withholdings	(221,596)	(3)	(221,593)
Vesting of restricted stock (in shares)		167,647
Vesting of restricted stock	0	17	(17)
Tax deficit of share-based compensation	(272,828)		(272,828)
Equity compensation	2,895,012		2,895,012
Stock repurchase and retirement (in shares)	(427,043)	(427,043)
Stock repurchase and retirement	(2,234,585)	(43)	(2,234,542)
Foreign currency translation adjustment	(939,000)			(939,000)
Reclassification of currency translation adjustments related to sale of clinical trial services business	0
Net change in fair value of marketable securities	(33,431)			(33,431)
Net income (loss)	4,097,849				4,097,849
Ending Balance at Dec. 31, 2011	249,300,297	3,081	243,170,554	(3,373,162)	9,499,824
Ending Balance (in shares) at Dec. 31, 2011		30,812,023
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of restricted stock (in shares)		161,944
Vesting of restricted stock	(152,430)	16	(152,446)
Tax deficit of share-based compensation	(314,314)		(314,314)
Equity compensation	2,594,523		2,594,523
Stock repurchase and retirement (in shares)	(71,653)	(71,653)
Stock repurchase and retirement	(374,248)	(7)	(374,241)
Foreign currency translation adjustment	267,809			267,809
Reclassification of currency translation adjustments related to sale of clinical trial services business	0
Net change in fair value of marketable securities	22,649			22,649
Net income (loss)	(42,221,497)				(42,221,497)
Ending Balance at Dec. 31, 2012	209,122,789	3,090	244,924,076	(3,082,704)	(32,721,673)
Ending Balance (in shares) at Dec. 31, 2012		30,902,314
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	14,000	2,362
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options		0
Vesting of restricted stock (in shares)		180,613
Vesting of restricted stock	(300,532)	19	(300,551)
Tax deficit of share-based compensation	(398,886)		(398,886)
Equity compensation	2,099,941		2,099,941
Foreign currency translation adjustment, net of deferred taxes	(223,610)			(223,610)
Foreign currency translation adjustment	(386,094)
Reclassification of currency translation adjustments related to sale of clinical trial services business	2,336,201			2,336,201
Net income (loss)	(51,969,323)
Ending Balance at Dec. 31, 2013	$ 160,666,580	$ 3,109	$ 246,324,580	$ (970,113)	$ (84,690,996)
Ending Balance (in shares) at Dec. 31, 2013		31,085,289